mRNA Vaccine Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By mRNA Type, By Application, Region and Competition, 2020-2030F

Description

Global mRNA Vaccine Market was valued at USD 11.45 billion in 2024 and is expected to reach USD 18.37 Billion by 2030 with a CAGR of 8.34% during the forecast period. The global mRNA Vaccine market has experienced rapid growth driven by the success of COVID-19 vaccines and the expanding potential of the technology. For instance, according to WHO, cardiovascular diseases (CVDs) are the world's leading cause of death, claiming around 17.9 million lives annually. They include heart and blood vessel disorders, with most deaths caused by heart attacks and strokes, often affecting people under 70.

Market Overview
Forecast Period	2026-2030
Market Size 2024	USD 11.45 Billion
Market Size 2030	USD 18.37 Billion
CAGR 2025-2030	8.34%
Fastest Growing Segment	COVID-19 m RNA Vaccines
Largest Market	North America

mRNA Vaccines use a synthetic version of messenger RNA to instruct cells to produce proteins that trigger an immune response. This method enables faster development and manufacturing compared to traditional vaccine platforms. The market is no longer limited to infectious diseases, as ongoing research explores mRNA's application in cancer immunotherapy, genetic disorders, and autoimmune conditions. Advancements in lipid nanoparticle delivery systems have improved the stability and efficiency of mRNA Vaccines, opening new opportunities for therapeutic innovation. Companies are investing heavily in expanding mRNA research pipelines and manufacturing infrastructure to support long-term demand. Regulatory agencies are also adapting to accommodate the rapid pace of development associated with mRNA technologies. The rise in public awareness and acceptance of mRNA Vaccines has further boosted adoption across various geographies. While challenges such as cold chain logistics and high production costs remain, the market continues to evolve with new entrants and strategic collaborations. As technology matures, mRNA Vaccines are expected to become a cornerstone of modern preventive and therapeutic medicine, offering targeted, personalized, and scalable healthcare solutions.

Key Market Drivers

Rising Demand for Rapid Vaccine Development

The rising demand for rapid vaccine development is a major force driving the global mRNA Vaccine market. For instance, on 29 July 2024, Bio-Manguinhos/Fiocruz, one of Latin America's largest vaccine manufacturers, joined CEPI's Global South network. This partnership aims to enhance rapid and equitable vaccine responses to emerging infectious diseases by expanding manufacturing capacity across the Latin American and Caribbean region, strengthening preparedness for future epidemic and pandemic threats through localized production and regional collaboration. Traditional vaccine development can take years, involving complex cultivation, inactivation, or protein purification processes. In contrast, mRNA Vaccines can be designed and produced within weeks once a target pathogen's genetic sequence is known. This speed has become crucial in responding to public health emergencies, as demonstrated during the COVID-19 pandemic. Governments, healthcare organizations, and pharmaceutical companies now recognize the importance of having platforms that allow for quick vaccine adaptation and deployment. mRNA technology offers a flexible and programmable approach. By simply changing the mRNA sequence, developers can target new variants or different diseases without overhauling the entire production process. This flexibility allows for rapid response not only to pandemics but also to emerging infectious threats and seasonal outbreaks. The global health landscape is increasingly shaped by unpredictable disease patterns, making rapid vaccine development a strategic priority.

The ability to accelerate vaccine research and approval timelines also aligns with global efforts to strengthen pandemic preparedness. Investments are being directed toward expanding mRNA production infrastructure, streamlining regulatory pathways, and establishing stockpiles of platform technologies. As demand grows for adaptable and efficient vaccine solutions, mRNA platforms are emerging as essential tools in modern immunization strategies.

Key Market Challenges

Cold chain and storage requirements

Cold chain and storage requirements present a significant challenge to the growth and accessibility of the global mRNA Vaccine market. Unlike traditional vaccines that can often be stored at standard refrigeration temperatures, many first-generation mRNA Vaccines require ultra-cold storage conditions, sometimes as low as -70°C. These extreme requirements create logistical hurdles, especially in developing countries or remote regions where ultra-low temperature freezers and reliable electricity are limited or unavailable. Maintaining the cold chain from manufacturing facilities to administration sites demands specialized equipment, constant temperature monitoring, and trained personnel. Any break in this chain can compromise the integrity and efficacy of the vaccine, leading to waste and reduced immunization rates. This complexity increases distribution costs and slows down deployment, particularly during mass vaccination campaigns or emergency responses.

Efforts are being made to develop mRNA Vaccines that are more stable at higher temperatures, which would simplify storage and handling. Some newer formulations have achieved stability at standard refrigeration levels for limited durations, offering hope for wider accessibility. However, such innovations are still under development and not yet broadly available for all mRNA-based products. Until more thermostable solutions become mainstream, the cold chain will remain a critical limiting factor. Addressing this issue is essential for expanding the reach of mRNA Vaccines globally, especially in regions with fragile healthcare infrastructure.

Key Market Trends

Diversification Into Therapeutics Beyond Vaccines

Diversification into therapeutics beyond vaccines is transforming the landscape of the global mRNA Vaccine market. While initial breakthroughs centered on infectious diseases like COVID-19, mRNA technology is now being harnessed for a broad spectrum of therapeutic applications. Oncology is a primary focus, where personalized cancer vaccines use patient-specific tumor mutations to train the immune system to target malignant cells. Companies like BioNTech and Moderna are actively developing clinical programs aimed at various cancers, including melanoma, lung, and pancreatic types.

The appeal of mRNA in oncology lies in its adaptability and speed. Developers can rapidly design and produce vaccines that match an individual's cancer profile, offering a level of customization that traditional therapies cannot provide. This approach not only enhances treatment precision but also opens the door to more effective combination therapies with checkpoint inhibitors or immunomodulators. In genetic disorders, mRNA therapies are being explored as a way to replace faulty or missing proteins. Diseases such as cystic fibrosis or certain metabolic conditions are potential targets, where mRNA could provide temporary yet repeated protein correction. This method offers a less invasive and potentially safer alternative to gene editing technologies. Autoimmune diseases are also emerging as a new frontier. mRNA may help retrain the immune system to tolerate self-antigens, offering novel treatments for conditions like multiple sclerosis or type 1 diabetes. This shift toward broader therapeutic use signals a long-term evolution of the mRNA platform beyond its vaccine origins.

Key Market Players

Arcturus Therapeutics Holdings Inc.
BioNTech SE
CureVac N.V.
Daiichi Sankyo Company Limited.
Ethris GmbH
GlaxoSmithKline plc
Gennova Biopharmaceuticals Ltd
Moderna, Inc.
Pantherna Therapeutics GmbH
Providence Therapeutics

Report Scope:

In this report, the Global MRNA Vaccine Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

mRNA Vaccine Market, By mRNA Type:

Nucleoside-modified mRNA
Unmodified mRNA
Self-Amplifying mRNA

mRNA Vaccine Market, By Application:

COVID-19 mRNA Vaccines
Non COVID-19 mRNA Vaccines
Others

mRNA Vaccine Market, By Region:

North America
- United States
- Canada
- Mexico
Europe
- France
- United Kingdom
- Italy
- Germany
- Spain
Asia-Pacific
- China
- India
- Japan
- Australia
- South Korea
South America
- Brazil
- Argentina
- Colombia
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global MRNA Vaccine Market.

Available Customizations:

Global MRNA Vaccine Market report with the given Market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

1. Product Overview

1.1. Market Definition
1.2. Scope of the Market
- 1.2.1. Markets Covered
- 1.2.2. Years Considered for Study
- 1.2.3. Key Market Segmentations

2. Research Methodology

2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations

3. Executive Summary

3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends

4. Clinical Trial Analysis

4.1. Ongoing Clinical Trials
4.2. Completed Clinical Trials
4.3. Terminated Clinical Trials
4.4. Breakdown of Pipeline, By Development Phase
4.5. Breakdown of Pipeline, By Status
4.6. Breakdown of Pipeline, By Study Type
4.7. Breakdown of Pipeline, By Region
4.8. Clinical Trials Heat Map

5. Voice of Customer

6. Global mRNA Vaccine Market Outlook

6.1. Market Size & Forecast
- 6.1.1. By Value
6.2. Market Share & Forecast
- 6.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 6.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 6.2.3. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
- 6.2.4. By Company (20242)
6.3. Product Market Map
- 6.3.1. By mRNA Type
- 6.3.2. By Application
- 6.3.3. By Region

7. North America mRNA Vaccine Market Outlook

7.1. Market Size & Forecast
- 7.1.1. By Value
7.2. Market Share & Forecast
- 7.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 7.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 7.2.3. By Country
7.3. North America: Country Analysis
- 7.3.1. United States mRNA Vaccine Market Outlook
  - 7.3.1.1. Market Size & Forecast
    - 7.3.1.1.1. By Value
  - 7.3.1.2. Market Share & Forecast
    - 7.3.1.2.1. By mRNA Type
    - 7.3.1.2.2. By Application
- 7.3.2. Canada mRNA Vaccine Market Outlook
  - 7.3.2.1. Market Size & Forecast
    - 7.3.2.1.1. By Value
  - 7.3.2.2. Market Share & Forecast
    - 7.3.2.2.1. By mRNA Type
    - 7.3.2.2.2. By Application
- 7.3.3. Mexico mRNA Vaccine Market Outlook
  - 7.3.3.1. Market Size & Forecast
    - 7.3.3.1.1. By Value
  - 7.3.3.2. Market Share & Forecast
    - 7.3.3.2.1. By mRNA Type
    - 7.3.3.2.2. By Application

8. Europe mRNA Vaccine Market Outlook

8.1. Market Size & Forecast
- 8.1.1. By Value
8.2. Market Share & Forecast
- 8.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 8.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 8.2.3. By Country
8.3. Europe: Country Analysis
- 8.3.1. France mRNA Vaccine Market Outlook
  - 8.3.1.1. Market Size & Forecast
    - 8.3.1.1.1. By Value
  - 8.3.1.2. Market Share & Forecast
    - 8.3.1.2.1. By mRNA Type
    - 8.3.1.2.2. By Application
- 8.3.2. Germany mRNA Vaccine Market Outlook
  - 8.3.2.1. Market Size & Forecast
    - 8.3.2.1.1. By Value
  - 8.3.2.2. Market Share & Forecast
    - 8.3.2.2.1. By mRNA Type
    - 8.3.2.2.2. By Application
- 8.3.3. United Kingdom mRNA Vaccine Market Outlook
  - 8.3.3.1. Market Size & Forecast
    - 8.3.3.1.1. By Value
  - 8.3.3.2. Market Share & Forecast
    - 8.3.3.2.1. By mRNA Type
    - 8.3.3.2.2. By Application
- 8.3.4. Italy mRNA Vaccine Market Outlook
  - 8.3.4.1. Market Size & Forecast
    - 8.3.4.1.1. By Value
  - 8.3.4.2. Market Share & Forecast
    - 8.3.4.2.1. By mRNA Type
    - 8.3.4.2.2. By Application
- 8.3.5. Spain mRNA Vaccine Market Outlook
  - 8.3.5.1. Market Size & Forecast
    - 8.3.5.1.1. By Value
  - 8.3.5.2. Market Share & Forecast
    - 8.3.5.2.1. By mRNA Type
    - 8.3.5.2.2. By Application

9. Asia-Pacific mRNA Vaccine Market Outlook

9.1. Market Size & Forecast
- 9.1.1. By Value
9.2. Market Share & Forecast
- 9.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 9.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 9.2.3. By Country
9.3. Asia-Pacific: Country Analysis
- 9.3.1. China mRNA Vaccine Market Outlook
  - 9.3.1.1. Market Size & Forecast
    - 9.3.1.1.1. By Value
  - 9.3.1.2. Market Share & Forecast
    - 9.3.1.2.1. By mRNA Type
    - 9.3.1.2.2. By Application
- 9.3.2. India mRNA Vaccine Market Outlook
  - 9.3.2.1. Market Size & Forecast
    - 9.3.2.1.1. By Value
  - 9.3.2.2. Market Share & Forecast
    - 9.3.2.2.1. By mRNA Type
    - 9.3.2.2.2. By Application
- 9.3.3. Japan mRNA Vaccine Market Outlook
  - 9.3.3.1. Market Size & Forecast
    - 9.3.3.1.1. By Value
  - 9.3.3.2. Market Share & Forecast
    - 9.3.3.2.1. By mRNA Type
    - 9.3.3.2.2. By Application
- 9.3.4. South Korea mRNA Vaccine Market Outlook
  - 9.3.4.1. Market Size & Forecast
    - 9.3.4.1.1. By Value
  - 9.3.4.2. Market Share & Forecast
    - 9.3.4.2.1. By mRNA Type
    - 9.3.4.2.2. By Application
- 9.3.5. Australia mRNA Vaccine Market Outlook
  - 9.3.5.1. Market Size & Forecast
    - 9.3.5.1.1. By Value
  - 9.3.5.2. Market Share & Forecast
    - 9.3.5.2.1. By mRNA Type
    - 9.3.5.2.2. By Application

10. South America mRNA Vaccine Market Outlook

10.1. Market Size & Forecast
- 10.1.1. By Value
10.2. Market Share & Forecast
- 10.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 10.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 10.2.3. By Country
10.3. South America: Country Analysis
- 10.3.1. Brazil mRNA Vaccine Market Outlook
  - 10.3.1.1. Market Size & Forecast
    - 10.3.1.1.1. By Value
  - 10.3.1.2. Market Share & Forecast
    - 10.3.1.2.1. By mRNA Type
    - 10.3.1.2.2. By Application
- 10.3.2. Argentina mRNA Vaccine Market Outlook
  - 10.3.2.1. Market Size & Forecast
    - 10.3.2.1.1. By Value
  - 10.3.2.2. Market Share & Forecast
    - 10.3.2.2.1. By mRNA Type
    - 10.3.2.2.2. By Application
- 10.3.3. Colombia mRNA Vaccine Market Outlook
  - 10.3.3.1. Market Size & Forecast
    - 10.3.3.1.1. By Value
  - 10.3.3.2. Market Share & Forecast
    - 10.3.3.2.1. By mRNA Type
    - 10.3.3.2.2. By Application

11. Middle East and Africa mRNA Vaccine Market Outlook

11.1. Market Size & Forecast
- 11.1.1. By Value
11.2. Market Share & Forecast
- 11.2.1. By mRNA Type (Nucleoside-modified mRNA, Unmodified mRNA, Self-Amplifying mRNA)
- 11.2.2. By Application (COVID-19 mRNA Vaccines, Non COVID-19 mRNA Vaccines, Others)
- 11.2.3. By Country
11.3. MEA: Country Analysis
- 11.3.1. South Africa mRNA Vaccine Market Outlook
  - 11.3.1.1. Market Size & Forecast
    - 11.3.1.1.1. By Value
  - 11.3.1.2. Market Share & Forecast
    - 11.3.1.2.1. By mRNA Type
    - 11.3.1.2.2. By Application
- 11.3.2. Saudi Arabia mRNA Vaccine Market Outlook
  - 11.3.2.1. Market Size & Forecast
    - 11.3.2.1.1. By Value
  - 11.3.2.2. Market Share & Forecast
    - 11.3.2.2.1. By mRNA Type
    - 11.3.2.2.2. By Application
- 11.3.3. UAE mRNA Vaccine Market Outlook
  - 11.3.3.1. Market Size & Forecast
    - 11.3.3.1.1. By Value
  - 11.3.3.2. Market Share & Forecast
    - 11.3.3.2.1. By mRNA Type
    - 11.3.3.2.2. By Application

12. Market Dynamics

12.1. Drivers
12.2. Challenges

13. Market Trends & Developments

13.1. Recent Developments
13.2. Merger Acquisition
13.3. Product launches

14. Global mRNA Vaccine Market: SWOT Analysis

15. Porter's Five Forces Analysis

15.1. Competition in the Industry
15.2. Potential of New Entrants
15.3. Power of Suppliers
15.4. Power of Customers
15.5. Threat of Substitute Products

16. Competitive Landscape

16.1. Arcturus Therapeutics Holdings Inc.
- 16.1.1. Business Overview
- 16.1.2. Product Offerings
- 16.1.3. Recent Developments
- 16.1.4. Financials (As Reported)
- 16.1.5. Key Personnel
- 16.1.6. SWOT Analysis
16.2. BioNTech SE
16.3. CureVac N.V.
16.4. Daiichi Sankyo Company Limited.
16.5. Ethris GmbH
16.6. GlaxoSmithKline plc
16.7. Gennova Biopharmaceuticals Ltd
16.8. Moderna, Inc.
16.9. Pantherna Therapeutics GmbH
16.10. Providence Therapeutics